635698-30-5

Basic information

• Product Name: 2,4-Dichloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine hydrochloride
• Synonyms: 2,4-Dichloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine hydrochloride;3-d]pyriMidine hydrochloride;8-tetrahydropyrido[4;2,4-Dichloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine hydrochloride(1:x)
• CAS NO: 635698-30-5
• Molecular Formula: C7H7Cl2N3.ClH
• Molecular Weight: 240.52
• Mol File: 635698-30-5.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2,4-Dichloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Dichloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine hydrochloride(635698-30-5)
• EPA Substance Registry System: 2,4-Dichloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine hydrochloride(635698-30-5)

Safety Data

• Hazardous Substances Data: 635698-30-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H7Cl2N3.ClH/c8-6-4-3-10-2-1-5(4)11-7(9)12-6;/h10H,1-3H2;1H

Upstream product

• 635698-56-5 tert-butyl 2,4-dichloro-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate 
• 1454-53-1 ethyl 1-benzyl-4-oxopiperidine-3-carboxylate hydrochloride 
• 41276-30-6 C₉H₁₄O₃NC₆H₅ 
• 135481-57-1 5,6,7,8-tetrahydro-6-(phenylmethyl)pyrido<3,4-d>pyrimidine-2,4(1H,3H)-dione 
• 57611-47-9 1-benzyl-4-oxo-piperidine-3-carboxylic acid methyl ester 
• 1201781-22-7 2,4-dichloro-6-(1-chloroethoxycarbonyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine 
• 778574-06-4 6-benzyl-2,4-dichloro-5,6,7,8-tetrahydropyrido[4,3-d]-pyrimidine 

Relevant articles and documents

TOLL LIKE RECEPTOR MODULATOR COMPOUNDS

This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.

TREATMENT OF INFECTIOUS DISEASES WITH GLUCOSE UPTAKE INHIBITORS

Provided are methods of treating infectious diseases in mammals comprising administering a compound that inhibits glucose uptake. Particular infectious diseases that may be treated include malaria, leishmaniasis, African trypanosomiasis, tuberculosis, HIV, HCMV or herpes virus. In a first aspect, the invention features a method of treating infectious diseases in a mammal, comprising administering to a mammalian subject in need thereof a therapeutically effective amount of a compound or prodrug thereof, or pharmaceutically acceptable salt or ester of said compound or prodrug, wherein the compound is an inhibitor of glucose uptake.

BICYCLIC PYRIMIDINE DERIVATIVES

[wherein m and n may be the same or different and each represents an integer of 1 to 3 wherein m + n is 4 or less; R1 represents NR4R5 (wherein R4 and R5 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl or the like); R2 represents the above Formula (II), Formula (IV) or the like; A represents a single bond, -C(=O)-, -SO2-, -OC(=O)- or the like; and R3 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aralkyl or the like]ψBicyclic pyrimidine derivatives represented by the above Formula (I), or quaternary ammonium salts thereof, or pharmaceutically acceptable salts thereof, or the like, are provided. These have anti-inflammatory activities or modulation activities on the functions of TARC and/or MDC and are useful for treating and/or preventing a disease which is related to T cells, such as an allergic disease, an autoimmune disease or transplant rejection.